{
    "organizations": [],
    "uuid": "fe72b4fe611829138e5d0966eed40ab9abf298cf",
    "author": "Noemie Bisserbe",
    "url": "https://www.wsj.com/articles/novartis-ceo-steers-drug-maker-back-to-r-d-1518962400",
    "ord_in_thread": 0,
    "title": "Novartis CEO Steers Drug Maker Back to R&D",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Novartis AG has spent the past five years getting smaller. Its new chief executive has to decide soon how much more it will shrink.\n\nVasant Narasimhan, a 41-year-old Harvard-trained doctor, took the helm earlier this month at Novartis, the world’s No. 2 prescription-drug firm by sales after Pfizer Inc. Dr. Narasimhan has promised a technological revolution at Novartis to boost its drug-development pipeline. He inherits an empire that his predecessor spent most of his tenure pruning to focus more on its bread and butter—finding... To Read the Full Story Subscribe Sign In",
    "published": "2018-02-18T16:00:00.000+02:00",
    "crawled": "2018-02-18T16:56:55.012+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "novartis",
        "ag",
        "spent",
        "past",
        "five",
        "year",
        "getting",
        "smaller",
        "new",
        "chief",
        "executive",
        "decide",
        "soon",
        "much",
        "shrink",
        "vasant",
        "narasimhan",
        "doctor",
        "took",
        "helm",
        "earlier",
        "month",
        "novartis",
        "world",
        "firm",
        "sale",
        "pfizer",
        "narasimhan",
        "promised",
        "technological",
        "revolution",
        "novartis",
        "boost",
        "pipeline",
        "inherits",
        "empire",
        "predecessor",
        "spent",
        "tenure",
        "pruning",
        "focus",
        "bread",
        "read",
        "full",
        "story",
        "subscribe",
        "sign"
    ]
}